• Eupraxia Pharmaceuticals published MD&A for three months ended March 31, 2026, highlighting continued focus on EP-104GI for eosinophilic esophagitis while evaluating funding alternatives for EP-104IAR osteoarthritis program, including potential partnerships.
• RESOLVE Phase 1b/2a dose-escalation enrollment completed with no dose-limiting toxicities or drug-related serious adverse events; symptom and biopsy measures improved with higher doses, with responses maintained in available follow-up data.
• Randomized, blinded, vehicle-controlled Phase 2b dose-optimization portion targets about 120 patients; interim data expected in Q4 2026.
• Cash and cash equivalents totaled USD 58.5 million at March 31, 2026; short-term investments were USD 80.38 million; net loss was USD 12.65 million for quarter.
• Existing cash, cash equivalents, combined with proceeds from exercise of EPRX.WT.A warrants expected to fund planned operations into second half of 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.